Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Coherus Oncology Inc. | Toripalimab in combination with nab-paclitaxel (nab-P) - (TORCHLIGHT) | Metastatic or recurrent triple-negative breast cancer (TNBC) | Phase 3 | Data Released | Intravenous | Oncology |
| Coherus Oncology Inc. | SRF388 + Atezolizumab + Bevacizumab | Hepatocellular carcinoma (HCC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Coherus Oncology Inc. | SRF388 | Non-small-cell lung cancer (NSCLC) | Phase 2 | Data Released | intravenous | Oncology |
| Coherus Oncology Inc. | Toripalimab - (JUPITER-08) | Extensive stage SCLC | Phase 3 | Intravenous | Oncology | |
| Coherus Oncology Inc. | Toripalimab + platinum-doublet chemotherapy - (NEOTORCH) | NSCLC neoadjuvant setting | Phase 3 | Intravenous | Oncology | |
| Coherus Oncology Inc. | INO-3112 and LOQTORZI (toripalimab-tpzi) | HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC) | Phase 3 | Trial Planned | INO-3112 intramuscular LOQTORZI intravenous | Oncology |
| Collegium Pharmaceutical Inc. | Clonidine gel | Painful diabetic neuropathy (PDN) | Phase 2b | Trial Discontinued | Transdermal | Neurology |
| COMPASS Pathways Plc | COMP360 Psilocybin | Treatment Resistant Depression (TRD) | Phase 3 | Ongoing | Oral | Psychiatric |
